Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is SIRPaFc, an antibody-like fusion protein, which is in Phase I clinical trial that blocks the activity of CD47 to promote the macrophage-mediated killing of tumor cells in a range of cancers. It also develops CD200 monoclonal antibody that blocks the activity of CD200 to evade attack from the immune system. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.
http://www.priceseries.com/trade/TRIL-Trillium-Therapeutics-Inc-stock-gains-63-percent-a-Trade-Record-by-priceSeries-2017100520171109.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments